Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Neogenomics stock

NEO
US64049M2098
120159

Price

17.73
Today +/-
-0.16
Today %
-0.95 %

Neogenomics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Neogenomics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Neogenomics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Neogenomics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Neogenomics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Neogenomics Stock Price History

DateNeogenomics Price
12/13/202417.73 undefined
12/12/202417.90 undefined
12/11/202418.17 undefined
12/10/202418.43 undefined
12/9/202417.91 undefined
12/6/202417.76 undefined
12/5/202417.19 undefined
12/4/202418.01 undefined
12/3/202417.82 undefined
12/2/202418.00 undefined
11/29/202417.73 undefined
11/27/202417.74 undefined
11/26/202417.18 undefined
11/25/202416.93 undefined
11/22/202416.39 undefined
11/21/202415.39 undefined
11/20/202415.36 undefined
11/19/202415.36 undefined
11/18/202415.01 undefined
11/15/202415.04 undefined

Neogenomics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Neogenomics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Neogenomics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Neogenomics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Neogenomics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Neogenomics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Neogenomics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Neogenomics’s growth potential.

Neogenomics Revenue, EBIT and net profit per share

DateNeogenomics RevenueNeogenomics EBITNeogenomics Net Income
2026e806.16 M undefined-29.73 M undefined46.41 M undefined
2025e734.15 M undefined-59.95 M undefined25.47 M undefined
2024e668.44 M undefined-85.29 M undefined12.59 M undefined
2023591.64 M undefined-96.65 M undefined-87.97 M undefined
2022509.7 M undefined-153.1 M undefined-144.3 M undefined
2021484.3 M undefined-103.1 M undefined-8.3 M undefined
2020444.4 M undefined-11.9 M undefined4.2 M undefined
2019408.8 M undefined13 M undefined8 M undefined
2018276.7 M undefined12.3 M undefined6.1 M undefined
2017240.3 M undefined4 M undefined-10.9 M undefined
2016231.8 M undefined5.7 M undefined-30.8 M undefined
201599.8 M undefined-5.6 M undefined-2.7 M undefined
201487.1 M undefined2.2 M undefined1.1 M undefined
201366.5 M undefined3.2 M undefined2 M undefined
201259.9 M undefined1.2 M undefined100,000 undefined
201143.5 M undefined-400,000 undefined-1.2 M undefined
201034.4 M undefined-3 M undefined-3.3 M undefined
200929.5 M undefined-1.7 M undefined-2.2 M undefined
200820 M undefined-900,000 undefined-1.4 M undefined
200711.5 M undefined-3.1 M undefined-3.4 M undefined
20066.5 M undefined100,000 undefined-100,000 undefined
20051.9 M undefined-800,000 undefined-1 M undefined
2004600,000 undefined-700,000 undefined-800,000 undefined

Neogenomics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
00016112029344359668799231240276408444484509591668734806
----500.0083.3381.8245.0017.2426.4737.2111.8631.8213.79133.333.9015.0047.838.829.015.1716.1113.039.889.81
---24,400.0050.0054.5550.0051.7244.1244.1944.0746.9745.9843.4342.4242.5046.0148.0441.6738.6436.7441.2936.5333.2430.27
000036101515192631404398102127196185187187244000
000-10-3-1-2-3-1021-2-30-10684-8-144-87122546
-------66.67100.0050.00-66.67---50.00-300.001,400.00-66.67-160.0033.33-50.00-300.001,700.00-39.58-113.79108.3384.00
4.214.419.922.326.229.831.534.637.342.848.752.85660.577.579.491.6103.6111.8120124.2125.5000
-------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Neogenomics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Neogenomics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                         
00.100.10.20.51.61.12.61.94.833.723.412.512.89.8173296.3515.4438415.2
0.10.10.61.63.22.94.65.27.91418.720.548.955.560.476.994.2108.5113.9121.6131.26
000000000000000000000
000.10.10.30.50.60.91.21.92.32.65.16.37.58.714.429.523.424.324.16
000.10.10.40.51.71.51.50.81.724.94.55.28.3914.428.921.426.19
0.10.20.81.94.14.48.58.713.218.627.558.882.378.885.9103.7290.6448.7681.6605.3596.81
0.40.40.41.22.12.94.34.86.68.69.715.134.63436.560.990.7131.7211.7198.6183.78
0000000000000000029.6000
0000000000000000030020000
0000000002.82.64.287.877.174.2140126.6120.7442.3408.3373.13
000000000002.9146.4147147197.9198.6211.1527.1522.8522.77
00000.30.10.10.10.10.10.20.10.10.20.92.52.846.46.95.14.74
000000000.010.010.010.020.270.260.260.40.420.541.191.131.08
00000.010.010.010.010.020.030.040.080.350.340.340.510.710.991.871.741.68
                                         
000000000000.128.72332.70.10.10.10.10.10.13
0.010.010.010.010.020.020.020.020.030.030.040.080.230.220.230.370.520.71.121.161.19
-9.2-10-11-11.2-14.5-15.9-18.2-21.5-22.6-22.6-20.5-19.4-22.1-52.5-58.4-51.3-11.4-7.2-14.8-159.1-247.06
000-1000000000000300-600-1,6000-600-3,900-1,674
000000000000000000000
-0-0-00000.0100.010.010.020.060.240.190.20.320.510.691.1110.94
0.10.80.52.31.81.521.92.53.64.26.312.516.810.517.819.62517.920.520.33
00.10.10.20.91.11.81.82.93.53.15.113.612.615.62832.341.36361.873.84
0.10.10.100.40000000001.40.91.645.27.62.13
000001.10.63.43.98.54.308.900000000
0000.10.20.61.522.12.22.83.25.18.7914.210.42.81.10.10
0.210.72.63.34.35.99.111.417.814.414.640.138.136.560.963.973.187.29096.3
0000.40.81.41.51.32.63.13.35.357.497.496.498.195169.1532.6535.3538.2
00000000000.60.815.7156.722.515.65.455.534.824.29
0.601.4000000000000.33.127.646.486.28280.91
0.601.40.40.81.41.51.32.63.13.96.173.1112.4103.4123.7138.2220.9674.3652.1643.39
0.812.134.15.77.410.41420.918.320.7113.2150.5139.9184.6202.1294761.5742.1739.69
00000.010.010.010.010.020.030.040.080.350.340.340.50.710.991.871.741.68
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Neogenomics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Neogenomics's financial health and stability.

Assets

Neogenomics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Neogenomics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Neogenomics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Neogenomics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
000-10-3-1-2-3-1021-2-60284-8-144-87
000000011234572322213035536972
0000000000000000000000
0000-1-1-1-3-3-3-8-70-1-9-1212-32-61-4-31-25
000001233344371814142733-446563
0000000000110055642333
0000000000000000000000
00000-20-1-200296211844231-26-65-1
0000000000-3-2-3-2-7-13-14-20-29-64-30-28
0000000000-3-2-9-75-6-13-139-19-159-632076
000000000000-5-7210-1250-130-56831105
0000000000000000000000
00000-10-11-12-6-76027-6-1-119133100
000015050309360-51294171147423124
0000130322322958-25-491159235725114
--------1.00------3.00-2.00---1.00-3.00-29.00--
0000000000000000000000
00000001010228-10-100-31637766-5379
-0.81-0.59-0.75-1.02-1.09-3.17-0.64-2.46-2.97-0.83-4.140.225.684.1713.944.3530.483.34-27.64-90.86-96.88-30.71
0000000000000000000000

Neogenomics stock margins

The Neogenomics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Neogenomics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Neogenomics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Neogenomics's sales revenue. A higher gross margin percentage indicates that the Neogenomics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Neogenomics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Neogenomics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Neogenomics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Neogenomics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Neogenomics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Neogenomics Margin History

Neogenomics Gross marginNeogenomics Profit marginNeogenomics EBIT marginNeogenomics Profit margin
2026e41.34 %-3.69 %5.76 %
2025e41.34 %-8.17 %3.47 %
2024e41.34 %-12.76 %1.88 %
202341.34 %-16.34 %-14.87 %
202236.86 %-30.04 %-28.31 %
202138.63 %-21.29 %-1.71 %
202041.83 %-2.68 %0.95 %
201948.14 %3.18 %1.96 %
201846.01 %4.45 %2.2 %
201742.45 %1.66 %-4.54 %
201642.32 %2.46 %-13.29 %
201543.89 %-5.61 %-2.71 %
201446.73 %2.53 %1.26 %
201347.67 %4.81 %3.01 %
201244.74 %2 %0.17 %
201144.6 %-0.92 %-2.76 %
201045.93 %-8.72 %-9.59 %
200951.53 %-5.76 %-7.46 %
200853.5 %-4.5 %-7 %
200752.17 %-26.96 %-29.57 %
200656.92 %1.54 %-1.54 %
200542.11 %-42.11 %-52.63 %
200441.34 %-116.67 %-133.33 %

Neogenomics Stock Sales Revenue, EBIT, Earnings per Share

The Neogenomics earnings per share therefore indicates how much revenue Neogenomics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Neogenomics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Neogenomics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Neogenomics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Neogenomics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Neogenomics Revenue, EBIT and net profit per share

DateNeogenomics Sales per ShareNeogenomics EBIT per shareNeogenomics Earnings per Share
2026e6.28 undefined0 undefined0.36 undefined
2025e5.72 undefined0 undefined0.2 undefined
2024e5.21 undefined0 undefined0.1 undefined
20234.71 undefined-0.77 undefined-0.7 undefined
20224.1 undefined-1.23 undefined-1.16 undefined
20214.04 undefined-0.86 undefined-0.07 undefined
20203.97 undefined-0.11 undefined0.04 undefined
20193.95 undefined0.13 undefined0.08 undefined
20183.02 undefined0.13 undefined0.07 undefined
20173.03 undefined0.05 undefined-0.14 undefined
20162.99 undefined0.07 undefined-0.4 undefined
20151.65 undefined-0.09 undefined-0.04 undefined
20141.56 undefined0.04 undefined0.02 undefined
20131.26 undefined0.06 undefined0.04 undefined
20121.23 undefined0.02 undefined0 undefined
20111.02 undefined-0.01 undefined-0.03 undefined
20100.92 undefined-0.08 undefined-0.09 undefined
20090.85 undefined-0.05 undefined-0.06 undefined
20080.63 undefined-0.03 undefined-0.04 undefined
20070.39 undefined-0.1 undefined-0.11 undefined
20060.25 undefined0 undefined-0 undefined
20050.09 undefined-0.04 undefined-0.04 undefined
20040.03 undefined-0.04 undefined-0.04 undefined

Neogenomics business model

Neogenomics Inc. is a leading company in the field of personalized medicine, based in Fort Myers, Florida. It offers integrated diagnostics and pharmaceutical services for oncology and gene therapy, with a focus on providing accurate diagnosis for cancer patients. Neogenomics is one of the most popular companies on Eulerpool.com.

Neogenomics SWOT Analysis

Strengths

Neogenomics Inc holds a prominent position in the molecular testing and genetic analysis market. Its advanced technologies and expertise in oncology diagnostics give it a competitive advantage.

The company offers a wide range of testing services, including genetic testing, cytogenetics, flow cytometry, and pathology consultations. This diverse portfolio allows Neogenomics to cater to various customer needs.

Neogenomics has established collaborations with pharmaceutical companies, research institutions, and healthcare providers. These partnerships enhance its research capabilities and provide access to a larger customer base.

Weaknesses

The company operates in a highly regulated industry where changes in compliance requirements can impact its operations. Ensuring adherence to evolving regulations can be a potential weakness.

Neogenomics relies on reimbursement from insurance providers and government programs for its testing services. Any changes in reimbursement policies may affect the company's financial performance.

Maintaining advanced testing technologies and the need for highly skilled professionals contribute to Neogenomics' higher operating costs compared to some competitors.

Opportunities

The growing focus on personalized medicine creates opportunities for Neogenomics to expand its genetic testing services. Precision medicine can enhance treatment outcomes and drive demand for the company's advanced diagnostics.

The emergence of liquid biopsy as a non-invasive method for cancer detection presents an opportunity for Neogenomics. Investing in this technology can help the company capture a significant share of the liquid biopsy market.

Neogenomics can explore new markets beyond the United States to broaden its customer base. International expansion can provide access to untapped revenue streams and diversify its geographical risk.

Threats

The molecular testing and genetic analysis market is highly competitive, with several established players. Neogenomics faces the risk of losing market share to competitors that offer similar or more innovative services.

Rapid advancements in technology can quickly make existing diagnostic techniques obsolete. Neogenomics needs to stay at the forefront of technological developments to remain competitive and meet evolving customer expectations.

During periods of economic recession or downturns in healthcare spending, Neogenomics may experience a decline in demand for its high-cost testing services. The company needs to be prepared for potential fluctuations in market demand.

Neogenomics Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Neogenomics Revenue by Segment

Segmente20192018
Client direct billing212.7 M USD164.89 M USD
Commercial Insurance83.11 M USD40.36 M USD
Medicare and Medicaid64.75 M USD35.57 M USD
Self-Pay606,000 USD1.06 M USD

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Neogenomics Revenue by Segment

Segmente20192018
Clinical Services361.16 M USD241.87 M USD
Clinical Services Segment-241.87 M USD
Pharma Services47.67 M USD34.87 M USD
Pharma Services Segment-34.87 M USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Neogenomics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Neogenomics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Neogenomics shares outstanding

The number of shares was Neogenomics in 2023 — This indicates how many shares 125.502 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Neogenomics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Neogenomics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Neogenomics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Neogenomics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Neogenomics stock splits

In Neogenomics's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Neogenomics.

Neogenomics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20240.01 0.05  (296.83 %)2024 Q3
6/30/2024-0 0.03  (869.23 %)2024 Q2
3/31/2024-0.05 -0.02  (59.68 %)2024 Q1
12/31/2023-0.03 0.03  (219.05 %)2023 Q4
9/30/2023-0.08 0  (100 %)2023 Q3
6/30/2023-0.11 -0.05  (56.41 %)2023 Q2
3/31/2023-0.15 -0.09  (41.1 %)2023 Q1
12/31/2022-0.17 -0.06  (63.94 %)2022 Q4
9/30/2022-0.21 -0.14  (32.66 %)2022 Q3
6/30/2022-0.23 -0.16  (29.7 %)2022 Q2
1
2
3
4
5
...
8

Eulerpool ESG Scorecard© for the Neogenomics stock

Eulerpool World ESG Rating (EESG©)

41/ 100

🌱 Environment

19

👫 Social

35

🏛️ Governance

71

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees59
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Neogenomics shareholders

%
Name
Stocks
Change
Date
14.20348 % BlackRock Institutional Trust Company, N.A.18,231,587-189,6496/30/2024
10.98153 % The Vanguard Group, Inc.14,095,892-89,5296/30/2024
6.83341 % Brown Advisory8,771,361-898,4146/30/2024
5.24329 % T. Rowe Price Investment Management, Inc.6,730,283-127,2986/30/2024
5.15685 % Janus Henderson Investors6,619,336338,4706/30/2024
3.80035 % State Street Global Advisors (US)4,878,133-19,6336/30/2024
3.72775 % Greenhouse Funds LLLP4,784,941388,5876/30/2024
3.27098 % Schroder Investment Management North America Inc.4,198,6321,094,5296/30/2024
2.94684 % First Light Asset Management, LLC3,782,561480,3966/30/2024
2.59008 % Dimensional Fund Advisors, L.P.3,324,624217,6876/30/2024
1
2
3
4
5
...
10

Neogenomics Executives and Management Board

Mr. Christopher Smith

(60)
Neogenomics Chief Executive Officer, Director (since 2022)
Compensation 14.8 M

Mr. Vishal Sikri

(47)
Neogenomics President - Advanced Diagnostics
Compensation 3.36 M

Mr. Jeffrey Sherman

(57)
Neogenomics Chief Financial Officer
Compensation 3.27 M

Dr. Shashikant Kulkarni

(56)
Neogenomics Executive Vice President of Research and Development, Chief Scientific Officer
Compensation 2.67 M

Mr. Warren Stone

(50)
Neogenomics President - Clinical Services
Compensation 2.39 M
1
2
3
4

Neogenomics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Community Health Systems Stock
Community Health Systems
SupplierCustomer0,680,700,770,740,580,04
QIAGEN Stock
QIAGEN
SupplierCustomer0,480,760,330,870,700,50
Elevation Oncology Stock
Elevation Oncology
SupplierCustomer0,290,16-0,310,78
PPD, Inc. Stock
PPD, Inc.
SupplierCustomer0,110,15-0,84-0,90-0,68
Thermo Fisher Scientific Stock
Thermo Fisher Scientific
SupplierCustomer0,090,650,250,790,02-0,32
FedEx Stock
FedEx
SupplierCustomer-0,31 0,560,720,690,43
1

Most common questions regarding Neogenomics

What values and corporate philosophy does Neogenomics represent?

Neogenomics Inc prides itself on its commitment to excellence and innovation in the field of precision medicine. With a strong corporate philosophy centered around patient care and advancing the fight against cancer, Neogenomics Inc places great importance on ethical practices and providing accurate diagnostic solutions. The company believes in fostering a collaborative environment to bring cutting-edge technologies and personalized medicine to patients globally. By constantly pushing boundaries and embracing transformative ideas, Neogenomics Inc aims to revolutionize how cancer is detected and treated. Through its dedication to quality, integrity, and patient-centric values, the company sets itself apart as a leader in the field.

In which countries and regions is Neogenomics primarily present?

Neogenomics Inc is primarily present in the United States.

What significant milestones has the company Neogenomics achieved?

Some significant milestones achieved by Neogenomics Inc include its acquisition of Clarient Inc in 2015, which expanded its personalized medicine capabilities. The company also received full approval from the New York State Department of Health in 2017, allowing it to offer its services in all 50 states. Neogenomics Inc has strengthened its position in the molecular testing market through strategic collaborations with pharmaceutical companies. Furthermore, in 2019, the company completed its acquisition of Genoptix, enhancing its oncology diagnostics capabilities. These milestones demonstrate Neogenomics Inc's commitment to growth and innovation in the field of cancer diagnostics and personalized medicine.

What is the history and background of the company Neogenomics?

Neogenomics Inc is a leading provider of cancer-focused genetic testing services. Founded in 2001, the company is headquartered in Fort Myers, Florida. With an extensive network of laboratories across the United States, Neogenomics offers cutting-edge diagnostic and pharmaceutical services to aid in the personalized treatment and monitoring of various types of cancers. Over the years, Neogenomics has grown its portfolio of tests and services, catering to the evolving needs of healthcare professionals and patients. Their dedication to innovation and quality has positioned them as a trusted partner in the fight against cancer.

Who are the main competitors of Neogenomics in the market?

The main competitors of Neogenomics Inc in the market are Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, and NeoGenomics Laboratories.

In which industries is Neogenomics primarily active?

Neogenomics Inc is primarily active in the healthcare and diagnostic laboratory services industries.

What is the business model of Neogenomics?

Neogenomics Inc. (NYSE: NEO) is a leading provider of cancer-focused genetic testing services. The company's business model revolves around offering comprehensive testing solutions that aid in the diagnosis and treatment of cancer patients. Neogenomics Inc. operates through a network of laboratories and provides advanced molecular and cytogenetic testing, helping healthcare professionals make informed decisions based on genetic information. With a focus on precision medicine, Neogenomics Inc. delivers personalized treatment options, improving patient outcomes and delivering high-quality diagnostic services.

What is the P/E ratio of Neogenomics 2024?

The Neogenomics P/E ratio is 176.69.

What is the P/S ratio of Neogenomics 2024?

The Neogenomics P/S ratio is 3.33.

What is the Quality Investing of Neogenomics?

The Quality Investing for Neogenomics is 5/10.

What is the revenue of Neogenomics 2024?

The expected Neogenomics revenue is 668.44 M USD.

How high is the profit of Neogenomics 2024?

The expected Neogenomics profit is 12.59 M USD.

What is the business model of Neogenomics

Neogenomics Inc is a leading company in oncology diagnostics and offers a wide range of solutions and products to its customers. The company has been listed on the stock exchange since 2001 and is the largest provider of cancer diagnostics services in the United States. Translate the text to the best possible English.

What is the Neogenomics dividend?

Neogenomics pays a dividend of 0 USD distributed over payouts per year.

How often does Neogenomics pay dividends?

The dividend cannot currently be calculated for Neogenomics or the company does not pay out a dividend.

What is the Neogenomics ISIN?

The ISIN of Neogenomics is US64049M2098.

What is the Neogenomics WKN?

The WKN of Neogenomics is 120159.

What is the Neogenomics ticker?

The ticker of Neogenomics is NEO.

How much dividend does Neogenomics pay?

Over the past 12 months, Neogenomics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Neogenomics is expected to pay a dividend of 0 USD.

What is the dividend yield of Neogenomics?

The current dividend yield of Neogenomics is .

When does Neogenomics pay dividends?

Neogenomics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Neogenomics?

Neogenomics paid dividends every year for the past 0 years.

What is the dividend of Neogenomics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Neogenomics located?

Neogenomics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Neogenomics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Neogenomics from 12/15/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/15/2024.

When did Neogenomics pay the last dividend?

The last dividend was paid out on 12/15/2024.

What was the dividend of Neogenomics in the year 2023?

In the year 2023, Neogenomics distributed 0 USD as dividends.

In which currency does Neogenomics pay out the dividend?

The dividends of Neogenomics are distributed in USD.

All fundamentals about Neogenomics

Our stock analysis for Neogenomics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Neogenomics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.